Piper Sandler Reiterates Overweight on AbbVie, Maintains $298 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 51.4%

Neg 0% Neu 51.4% Pos 0%

Piper Sandler analyst David Amsellem reiterates AbbVie (NYSE:ABBV) with a Overweight and maintains $298 price target.

Comments

No comments yet. Be the first!